Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 8, 2025
HEPA$0.07-17.7%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
Date: April 8, 2025
| HEPION PHARMACEUTICALS, INC. | |
| By: | /s/ JOHN BRANCACCIO |
| John Brancaccio | |
| Interim Chief Executive Officer/Chief Financial Officer and Director (Interim Principal Executive Officer and Financial Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.